- Axelyf is a team spanning the US, UK and Iceland – experts with experience from Moderna and top biotech/pharma developing next-generation lipid nanoparticle delivery systems
- Lead investigational candidate AXL-003 is in early development for autoimmune disease
- Technology combines a potent new ionizable lipid library, novel surface chemistry and AI-informed design by a proprietary machine learning model